2026 BPI Boston Presentation: Advancing CHO Cell Line Development
September 24, 2026
BPI Boston 2026
Cell Line Development & Engineering Track
Hynes Convention Center, Boston, USA
12:30 pm ET
30 minute live presentation
Advancing CHO Cell Line Development:
A Dual-Strategy Approach Using Site-Specific and Transposon-Based Integration Platforms
Dennis Lin, PhD
Associate Director, Cell Line and Cell Culture Process Development
Abstract
As biologics pipelines diversify and development timelines tighten, cell line development (CLD) platforms are under increasing pressure to deliver faster progression, stable expression, and predictable product quality for increasingly complex molecules. Recent industry discussions have similarly emphasized the need to shorten CLD timelines while improving stability, predictability, and manufacturability. This presentation will describe Bora Biologics’ dual-strategy approach to cell line development, leveraging site-specific integration and transposon-based integration platforms to support flexible route selection based on molecule and program needs. Within Bora’s internal CLD framework, these platform options are positioned to support rapid CLD, stable clone uniformity, and representative product quality at the cell-pool stage. Case studies will illustrate how these two integration strategies can be applied to balance speed, productivity, and development risk, while enabling earlier decision-making during clone selection and process development. Public examples of transposon-based CLD platforms presented at BPI have likewise highlighted the value of representative pools, accelerated workflows, and earlier progression toward development milestones. Attendees will gain insight into how a dual-strategy integration framework can de-risk CHO cell line development, improve timeline flexibility, and support robust product quality outcomes in an increasingly competitive biologics landscape.
Presenter Bio
Dennis Lin, Ph.D., is a bioprocess development leader with extensive experience advancing therapeutic biologics from cell line development and GMP cell banking through upstream process development and scale-up up to 2,000 L. He currently serves as Associate Director, Cell Line and Cell Culture Process Development at Bora Biologics, where he leads CLD and CCPD strategy and supports IND-enabling CMC execution through cross-functional collaboration and CDMO partnerships. His expertise spans CHO, SP2/0, and NK cell platforms, with experience across more than 30 projects and diverse modalities including monoclonal antibodies, bispecific antibodies, complex proteins, biosimilars, and cell therapy. Prior to joining Bora Biologics, Dennis held roles at China Innovation Center of Roche, Canton Biologics, Lonza, Thermo Fisher Scientific, and Mycenax, where he contributed across GMP cell banking, upstream development, bioproduction applications, and commercial strategy. He earned his Ph.D. in Bioinformatics and Structural Biology from National Tsing Hua University, Taiwan.
